<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142762</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H2158-103</org_study_id>
    <nct_id>NCT04142762</nct_id>
  </id_info>
  <brief_title>A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate CYP3A4-Mediated, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess 1) the effect of multiple doses of itraconazole (CYP3A4
      inhibitor), rifampin (CYP3A4 inducer), and esomeprazole (pH modifier) on the pharmacokinetics
      of a single oral dose of ABI-H2158, and 2) the effect of steady-state oral ABI-H2158 on the
      pharmacokinetics of midazolam (sedative) and levonorgestrel/ethinyl estradiol (active oral
      contraceptive) in healthy adult participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Actual">January 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) of ABI-H2158</measure>
    <time_frame>before dosing and at pre-specified time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of ABI-H2158</measure>
    <time_frame>before dosing and at pre-specified time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Midazolam</measure>
    <time_frame>before dosing and at pre-specified time points up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Midazolam</measure>
    <time_frame>before dosing and at pre-specified time points up to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of ethinyl estradiol and levonorgestrel</measure>
    <time_frame>before dosing and at pre-specified time points up to 5 days after dosing on Day 21 of Cycle 1 and Cycle 2. Cycle 1 is 28 days and Cycle 2 is 26 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of ethinyl estradiol and levonorgestrel</measure>
    <time_frame>before dosing and at pre-specified time points up to 5 days after dosing on Day 21 of Cycle 1 and Cycle 2. Cycle 1 is 28 days and Cycle 2 is 26 days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ABI-H2158 + Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ABI-H2158 on Days 1 and 9; oral itraconazole once-daily (QD) on Days 6 through 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ABI-H2158 + Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ABI-H2158 on Days 1 and 12; oral rifampin QD on Days 6 through 16</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: ABI-H2158 + Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ABI-H2158 on Days 1 and 11; oral esomeprazole QD on Days 6 through 11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: ABI-H2158 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral midazolam on Days 1 and 11; oral ABI-H2158 QD on Days 2 through 11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: ABI-H2158 + Oral Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1: active oral contraceptive (ethinyl estradiol/levonorgestrel) QD on Days 1 through 21 and oral placebo QD on Days 22 through 28; Cycle 2: active oral contraceptive QD on Days 1 through 21, oral placebo QD on Days 22 through 26, and oral ABI-H2158 QD on Days 11 through 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H2158</intervention_name>
    <description>ABI-H2158 tablets</description>
    <arm_group_label>Cohort 1: ABI-H2158 + Itraconazole</arm_group_label>
    <arm_group_label>Cohort 2: ABI-H2158 + Rifampin</arm_group_label>
    <arm_group_label>Cohort 3: ABI-H2158 + Esomeprazole</arm_group_label>
    <arm_group_label>Cohort 4: ABI-H2158 + Midazolam</arm_group_label>
    <arm_group_label>Cohort 5: ABI-H2158 + Oral Contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Itraconazole capsules</description>
    <arm_group_label>Cohort 1: ABI-H2158 + Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin capsules</description>
    <arm_group_label>Cohort 2: ABI-H2158 + Rifampin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Midazolam syrup</description>
    <arm_group_label>Cohort 4: ABI-H2158 + Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol / Levonorgestrel</intervention_name>
    <description>Ethinyl Estradiol / Levonorgestrel tablets</description>
    <arm_group_label>Cohort 5: ABI-H2158 + Oral Contraceptive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole capsules</description>
    <arm_group_label>Cohort 3: ABI-H2158 + Esomeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching oral contraceptive</intervention_name>
    <description>Placebo matching Ethinyl Estradiol / Levonorgestrel tablets</description>
    <arm_group_label>Cohort 5: ABI-H2158 + Oral Contraceptive</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. No clinically significant abnormal findings on physical exam, medical history, or
             clinical laboratory results at screening.

          2. Cohort 5: naive to the use of oral contraceptives.

        Exclusion Criteria:

        1. Positive test results for human immunodeficiency virus (HIV) or hepatitis B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Lead</last_name>
    <role>Study Director</role>
    <affiliation>Assembly Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

